Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Conditions

• Paroxysmal Nocturnal Hemoglobinuria

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Pozelimab — DRUG
  Subcutaneous (SC) administration
• Cemdisiran — DRUG
  Subcutaneous (SC) administration

Study Details

This program is designed to provide access to pozelimab and cemdisiran and document the long-term safety of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare immune disease that causes red blood cells in your body to break apart.

Key Dates

Status verified

Oct 2025

Related Studies

• Global PNH Patient Registry
  Recruiting · Aplastic Anemia and MDS International Foundation · Bethesda, Maryland
• Home Reported Outcomes in PNH
  Recruiting · Novartis Pharmaceuticals · East Hanover, New Jersey
• MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
  PHASE2 · Recruiting · Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota
• The International PNH Interest Group PNH Registry
  Recruiting · International PNH Interest Group · Altamonte Springs, Florida